Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.

Macdonald HM, Nishiyama KK, Hanley DA, Boyd SK

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA11 May 2010Cited by 96 (Europe PMC)

PMID20458576DOI10.1007/s00198-010-1226-1PepBankPUB-20458576

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, distal radius total BMD decreased from baseline during teriparatide treatment.
In plain wordsIn women with osteoporosis, wrist total bone density decreased from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseDistal radius total BMD
Study
n = 11
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
After 18 months, we observed a decrease in total BMD (p = 0.03) at the distal radius and a decrease in cortical BMD at the distal radius (p = 0.05) and tibia (p = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to monitor changes in bone microarchitecture and strength at the distal radius and tibia associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
Report a problemFND-2045857601
02HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, distal radius cortical BMD decreased from baseline during teriparatide treatment.
In plain wordsIn women with osteoporosis, wrist cortical bone density decreased from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseDistal radius cortical BMD
Study
n = 11
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
After 18 months, we observed a decrease in total BMD (p = 0.03) at the distal radius and a decrease in cortical BMD at the distal radius (p = 0.05) and tibia (p = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to monitor changes in bone microarchitecture and strength at the distal radius and tibia associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
Report a problemFND-2045857602
03HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, distal tibia cortical BMD decreased from baseline during teriparatide treatment.
In plain wordsIn women with osteoporosis, shin cortical bone density decreased from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseDistal tibia cortical BMD
Study
n = 11
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
After 18 months, we observed a decrease in total BMD (p = 0.03) at the distal radius and a decrease in cortical BMD at the distal radius (p = 0.05) and tibia (p = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to monitor changes in bone microarchitecture and strength at the distal radius and tibia associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
Report a problemFND-2045857603
04HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, cortical BMD declines during teriparatide treatment accompanied trends toward increased cortical porosity at both sites.
In plain wordsIn women with osteoporosis, bone density declines during teriparatide treatment accompanied trends toward greater porosity at both sites.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedCortical porosity
Study
n = 11
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
The declines in cortical BMD were associated with trends for increased cortical porosity at both sites.
1 context sentence(design, population, supporting numbers)
Summary · context
We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to monitor changes in bone microarchitecture and strength at the distal radius and tibia associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
Report a problemFND-2045857604
05HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, teriparatide treatment was associated with distal radius trabecular thinning.
In plain wordsIn women with osteoporosis, wrist bone struts became thinner during teriparatide treatment compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseDistal radius trabecular thickness
Study
n = 11
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
At the distal radius, 18 months of teriparatide treatment was also associated with trabecular thinning (p = 0.009) and reduced trabecular bone volume ratio (p = 0.08).
1 context sentence(design, population, supporting numbers)
Summary · context
We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to monitor changes in bone microarchitecture and strength at the distal radius and tibia associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
Report a problemFND-2045857605
06HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, teriparatide treatment was associated with reduced distal radius trabecular bone volume ratio, with p = 0.08.
In plain wordsIn women with osteoporosis, wrist trabecular bone volume ratio declined during teriparatide treatment, with p = 0.08.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeDistal radius trabecular bone volume ratio
Study
n = 11
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
At the distal radius, 18 months of teriparatide treatment was also associated with trabecular thinning (p = 0.009) and reduced trabecular bone volume ratio (p = 0.08).
1 context sentence(design, population, supporting numbers)
Summary · context
We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to monitor changes in bone microarchitecture and strength at the distal radius and tibia associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
Report a problemFND-2045857606
07HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, distal tibia trabecular changes during teriparatide treatment showed trends similar to the distal radius.
In plain wordsIn women with osteoporosis, shin trabecular changes during teriparatide treatment showed trends similar to the wrist.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedDistal tibia trabecular changes
Study
n = 11
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
We observed similar trends at the distal tibia.
2 context sentences(design, population, supporting numbers)
Summary · context
At the distal radius, 18 months of teriparatide treatment was also associated with trabecular thinning (p = 0.009) and reduced trabecular bone volume ratio (p = 0.08).
Summary · context
We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to monitor changes in bone microarchitecture and strength at the distal radius and tibia associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
Report a problemFND-2045857607
08HumanNon-randomized trialEfficacy outcome
In osteoporotic postmenopausal women, estimated bone strength did not change significantly from baseline during teriparatide treatment.
In plain wordsIn women with osteoporosis, estimated bone strength did not change significantly from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeEstimated bone strength
Study
n = 11
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
Despite treatment-associated declines in total and cortical BMD, trabecular thinning and reduced trabecular bone volume, bone strength did not change significantly from baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
Despite these changes in bone quality, bone strength was maintained over the 18-month follow-up.
Summary · context
We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to monitor changes in bone microarchitecture and strength at the distal radius and tibia associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
Report a problemFND-2045857608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.